NanoSphere Health Sciences Inc AI Stock Analysis
Want to see TSE:NSHS.X full AI Analyst Report?
NanoSphere Health Sciences Inc (NSHS.X) AI Stock Analysis
NanoSphere Health Sciences Inc
(CNQX:NSHS.X)
Severe financial weakness is the primary factor, reinforced by bearish technical momentum and an unfavorable loss-based valuation. The weighted score is 38.25, rounded to 38.
NanoSphere Health Sciences Inc (NSHS.X) vs. iShares MSCI Canada ETF (EWC)
- Market Cap
- CAD 205.50K
- Dividend Yield
- ―
- Average Volume (3M)
- 5,916
- Price to Earnings (P/E)
- -1.8
- Beta (1Y)
- -2.66
- Revenue Growth
- ―
- EPS Growth
- -132.14%
- Country
- Canada
- Employees
- 5
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
NanoSphere Health Sciences Inc Business Overview & Revenue Model
Company Description
NanoSphere Health Sciences Inc. is a nano-biotechnology enterprise operating in the United States and Canada, specializing in the provision of biologically active compounds. The company's primary offering is the NanoSphere Delivery System, an innovat...
NanoSphere Health Sciences Inc Financial Statement Overview
Summary
No revenue, persistent net losses, deeply negative equity, minimal assets, and ongoing cash burn indicate severe financial distress despite low debt and slightly improving losses.
Income Statement
5Very NegativeBalance Sheet
8Very NegativeCash Flow
10Very Negative| Breakdown | TTM | Dec 2025 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITDA | -213.44K | -181.91K | -251.59K | -319.60K | -286.00K | -341.00K |
| Net Income | -83.07K | -86.27K | ― | -228.13K | -282.00K | -356.00K |
Balance Sheet | ||||||
| Total Assets | 16.81K | 16.81K | 13.59K | 17.97K | 60.05K | 132.51K |
| Cash, Cash Equivalents and Short-Term Investments | 1,882 | 1,882 | 2,022 | 9,316 | 55.01K | 130.76K |
| Total Debt | 57.14K | 57.14K | 30.71K | 0 | 0 | 0 |
| Total Liabilities | 1.37M | 1.37M | 1.23M | 1.57M | 1.37M | 1.21M |
| Stockholders Equity | -1.35M | -1.35M | -1.22M | -1.56M | -1.31M | -1.08M |
Cash Flow | ||||||
| Free Cash Flow | -24.33K | -23.38K | -35.92K | -53.70K | -67.66K | -64.68K |
| Operating Cash Flow | -24.33K | -23.38K | -35.92K | -53.70K | -67.66K | -64.68K |
| Investing Cash Flow | 0 | 0 | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 26.57K | 27.00K | 28.83K | 0 | 0 | 182.43K |
NanoSphere Health Sciences Inc Peers Comparison
Overall Rating
TSE:VXL43Neutral
TSE:NSHS.X38Underperform
TSE:CHGX24Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 43Neutral | CAD 458.16K | 1.15 | 34.52% | ― | ― | ― | |
| 38Underperform | CAD 256.88K | -1.76 | 6.14% | ― | ― | -132.14% | |
| 24Underperform | CAD 415.65K | -0.23 | 19.40% | ― | ― | ― |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TSE:NSHS.X | Nanosphere Health Sciences | 0.03 | 0.00 | 0.00% | |
| TSE:ABRT | Albert Labs International Corp. | 0.01 | 0.00 | 0.00% | |
| TSE:VXL | Vaxil Bio | 0.12 | -0.03 | -23.33% | |
| TSE:CHGX | Chitogenx Inc. | 0.01 | 0.00 | 0.00% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 24, 2026
